Recently a recombinant polypeptide of hepatitis C virus (HCV) has been developed by the Chiron Corporation in California. This antigen has been used to develop an ELISA test (Ortho Diagnostic Systems for serum anti-HCV antibodies. Preliminary data have shown that this virus is the major cause of NANB hepatitis in the world. We examined differences in anti-HCV prevalence among subgroups of blood donors (total sera examined 639) classified for past or present exposure to HBV or not, and for ALT levels. The anti-HCV prevalence found in regular blood donors with normal ALT levels and no antibody to HBcAg was 1.2%. No significant difference in the anti-HCV prevalence was found among other subgroups of blood donors except that a higher prevalence (10%) was found in a group with both elevated ALT and HBV markers. These preliminary findings suggest that the policy of blood supply should take into account the advent of HCV antibody test.
Antibodies to hepatitis C virus in blood donors / P. Ferroni, A. Tagger, M.L. Ribero, A. Grossi, F. Pregliasco, M.L. Pasquali, S. Salvaneschi. - In: EUROPEAN JOURNAL OF EPIDEMIOLOGY. - ISSN 0393-2990. - 6:3(1990 Sep), pp. 326-328.
|Titolo:||Antibodies to hepatitis C virus in blood donors|
TAGGER, ALESSANDRO (Secondo)
|Parole Chiave:||Hepacivirus; Humans ; Hepatitis Antibodies ; Enzyme-Linked Immunosorbent Assay ; Hepatitis C ; Blood Donors ; Prevalence|
|Settore Scientifico Disciplinare:||Settore MED/42 - Igiene Generale e Applicata|
|Data di pubblicazione:||set-1990|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/BF00150442|
|Appare nelle tipologie:||01 - Articolo su periodico|